PK

Perry Karsen

Chair Of The Board Of Directors at Nitrase Therapeutics

San Francisco Bay Area

Overview 

Perry Karsen is a highly accomplished biotechnology executive and board member based in the San Francisco Bay Area, known for his leadership roles at companies like Nitrase Therapeutics and Graphite Bio. With a strong educational background, including degrees from Stanford University and Northwestern University, he has made significant contributions to the biotech industry through his roles as Chair of the Board of Directors and Senior Advisor at various organizations, demonstrating a deep understanding of the sector and a track record of successful investments.

Work Experience 

NT

Nitrase Therapeutics

  • Chair Of The Board Of Directors

    2020 - Current

GB

Graphite Bio

  • Chair Of The Board Of Directors

    2020 - 2024

  • Board Member

    2020 - 2020

JT

Jounce Therapeutics, Inc.

  • Board Member

    2022 - 2023

  • Chair Of The Board Of Directors

    2016 - 2022

Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.

Raised $194,249,995.00 from Casdin Capital, Foresite Capital, Omega Funds, Wellington Management, Nextech Invest, Redmile Group, Cormorant Asset Management, Inbio Ventures and Pharmstandard.

jouncetx.com
SB

Samsara BioCapital

  • Senior Advisor

    2020 - 2022

Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies.

samsaracap.com
EB

ESCAPE Bio

  • Board Member

    2018 - 2022

IT

Intellia Therapeutics, Inc.

  • Board Member

    2020 - 2020

  • Chair Of The Board Of Directors

    2016 - 2020

VT

Voyager Therapeutics, Inc.

  • Board Of Directors

    2015 - 2019

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.

Raised $374,000,000.00 from Neurocrine Biosciences.

voyagertherapeutics.com
OP

OncoMed Pharmaceuticals

  • Executive Chair Of The Board Of Directors

    2016 - 2019

OncoMed Pharmaceuticals is a biotechnology company developing novel therapeutics for the treatment of cancer.

Raised $210,149,996.00 from Morgenthaler Ventures, Phase4 Ventures, The Vertical Group, U.S. Venture Partners, Delphi Ventures, Bay Partners, DeNovo Ventures, Adams Street Partners and Latterell Venture Partners.

oncomed.com
TR

Third Rock Ventures

  • Venture Partner

    2016 - 2018

PT

Pliant Therapeutics

  • Chair of the Board of Directors

    2016 - 2017

Education 

Investments 

Agios Pharmaceuticals

Series B

Total funding: $120M

Articles About Perry

Relevant Websites